

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

Attachment
October 2, 2026

【Therapeutic category】 Other antitumor agents
【Non-proprietary name】 Cladribine
【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current	Revision
9. PRECAUTIONS CONCERNING PATIENTS WITH SPECIFIC BACKGROUNDS 9.6 Breast-feeding Women <u>Breast-feeding is not recommended, because it is not known this drug is excreted in human breast milk.</u>	9. PRECAUTIONS CONCERNING PATIENTS WITH SPECIFIC BACKGROUNDS 9.6 Breast-feeding Women <u>Breast-feeding should be avoided for 7 days after the last dose. Cladribine has shown excreted into human breast milk.</u>

[Reference] Datta,P,et al.:Mult.Scler. 2021;27:799-801
Datta,P,et al.:Mult.Scler. 2023;29:1346-1347

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.